The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European CountriesVerena Hoffmann, Rüdiger Hehlmann, Sonja Burgstaller et al.|Leukemia|2015Cited by 255
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or AsciminibElias Jabbour, H. Kantarjian, Vivian G. Oehler et al.|JAMA Oncology|2024Cited by 26